• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Annex 13 Bulk Density and Tapped Density of Powders General Chapter

 

PDF Printer Version

CDER Logo

 

 

Guidance for Industry

Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions

Annex 13
Bulk Density and Tapped Density of Powders General Chapter

 

   

U. S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

May 2013
ICH


Guidance for Industry

Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the
ICH Regions

Annex 13
Bulk Density and Tapped Density of Powders General Chapter

Additional copies are available from:

Office of Communication, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
 10903 New Hampshire Ave., Bldg. 51, Room 2201
Silver Spring, MD 20993-0002
Phone: 301-796-3400; Fax: 301-847-8714; E-mail: druginfo@fda.hhs.gov
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

or

Office of Communication, Outreach and Development, HFM-40
Center for Biologics Evaluation and Research
 Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
(Tel) 800-835-4709 or 301-827-1800
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

 

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

May 2013
ICH

 

TABLE OF CONTENTS

 

I. INTRODUCTION (1)
II. Q4B OUTCOME (2)
A.    Analytical Procedures (2.1)
B.    Acceptance Criteria (2.2)
III.   TIMING OF ANNEX IMPLEMENTATION (3)
IV.   CONSIDERATIONS FOR IMPLEMENTATION (4)
A.    General Consideration (4.1)
B.    FDA Consideration (4.2)
C.    EU Consideration (4.3)
D.    MHLW Consideration (4.4)
E.    Health Canada Consideration (4.5)
V.    REFERENCES USED FOR THE Q4B EVALUATION (5)


Guidance for Industry _ftn1

Q4B Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions

Annex 13
Bulk Density and Tapped Density of Powders General Chapter

 

 This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic.  It does not create or confer any rights for or on any person and does not operate to bind FDA or the public.  You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations.  If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance.  If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.
 

INTRODUCTION (1)

_ftn2 

This annex is one in a series of guidance documents that describe the evaluations and recommendations by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions.  Implementation of the Q4B annexes is intended to avoid redundant testing by industry.  For general information on the Q4B process, the reader is referred to the core guidance Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions. _ftn3

This annex is the result of the Q4B process for the Bulk Density and Tapped Density of Powders Chapter.  The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II.         Q4B OUTCOME (2)

 

A.        Analytical Procedures (2.1)

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph. Eur. 2.9.34. Bulk Density and Tapped Density of Powders, JP 3.01 Determination of Bulk and Tapped Densities, and USP General Chapter <616> Bulk Density and Tapped Density of Powders, can be used as interchangeable in the ICH regions.

B.        Acceptance Criteria (2.2)

 

The texts evaluated did not contain acceptance criteria.

III.        TIMING OF ANNEX IMPLEMENTATION (3)    

 

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region.  Timing might differ for each region.

IV.       CONSIDERATIONS FOR IMPLEMENTATION (4)

 

A.        General Consideration (4.1)

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in section II.A (2.1) of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

B.        FDA Consideration (4.2)

 

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in sectionleft II.A (2.1) of this annex can be considered interchangeable.  However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

C.        EU Consideration (4.3)

 

For the European Union, regulatory authorities can accept the reference in a marketing authorization application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in section II.A (2.1), in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 2.9.34. on the basis of the declaration of interchangeability made above.

D.        MHLW Consideration (4.4)

 

The pharmacopoeial texts referenced in section II.A (2.1) of this annex can be used as interchangeable in accordance with the conditions set out in this annex.  Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

 E.       Health Canada Consideration (4.5)

 

In Canada any of the pharmacopoeial texts cited in section II.A (2.1) of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

V.        REFERENCES USED FOR THE Q4B EVALUATION (5)

 

A. (5.1The PDG Stage 5B sign-off document (Rev. 1 – Corr. 1):  Japanese Pharmacopoeial Forum, Volume 18, number 3 (September 2009).

B. (5.2)  The pharmacopoeial references for the Bulk Density and Tapped Density of Powders General Chapter for this annex are:

1. (5.2.1)  European Pharmacopoeia (Ph. Eur.):   Supplement 6.8 to Ph. Eur. 6th Edition (official July 2010), Bulk Density and Tapped Density of Powders (reference 07/2010:20934).

2. (5.2.2)  Japanese Pharmacopoeia (JP):  3.01 Determination of Bulk and Tapped Densities as it appears in the JP Sixteenth Edition (March 24, 2011, The Ministry of Health, Labour and Welfare Ministerial Notification No. 65).

3. (5.2.3)  United States Pharmacopeia (USP):  <616> Bulk Density and Tapped Density of Powders, USP 34, 2nd Supplement official December 1, 2011).

 

1.This guidance was developed within the Expert Working Group (Quality) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process.  This document has been endorsed by the ICH Steering Committee at Step 4 of the ICH process, June 2012.  At Step 4 of the process, the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan, and the United States.

2.Arabic numbers reflect the organizational breakdown of the document endorsed by the ICH Steering Committee at Step 4 of the ICH process, June 2012.

3.We update guidance documents periodically.  To make sure you have the most recent version of a guidance, check the FDA Drugs guidance page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/default.htm or the FDA Biologics guidance page at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.